IFN-λ gene polymorphisms as predictive factors in chronic hepatitis C treatment-naive patients without access to protease inhibitors

2015 ◽  
Vol 87 (10) ◽  
pp. 1702-1715 ◽  
Author(s):  
Daniele Blasquez Olmedo ◽  
Samária Ali Cader ◽  
Luís Cristóvão Porto
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Protease Inhibitors ◽  
Chronic Hepatitis C ◽  
Predictive Factors ◽  
Gene Polymorphisms ◽  
Hepatitis C Treatment ◽  
Treatment Naïve

scholarly journals Efficacy and direct costs of chronic hepatitis C treatment with first generation NS3/4A protease inhibitors in a real life population

2016 ◽  
Vol 4 ◽  
pp. 133-137
Author(s):  
Anna Piekarska ◽  
Ewa Koślińska-Berkan ◽  
Kamila Wójcik ◽  
Anna Skubała ◽  
Maciej Jabłkowski ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Protease Inhibitors ◽  
Chronic Hepatitis C ◽  
First Generation ◽  
Real Life ◽  
Direct Costs ◽  
Hepatitis C Treatment

scholarly journals The Presence of Non-organ-specific Autoantibodies in Chronic Hepatitis C Treatment-naive Patients

2022 ◽  
Author(s):  
Luis Jesuino de Oliveira Andrade ◽  
Ingrid Silva Santos Padilha ◽  
Luis Matos de Oliveira ◽  
Gabriela Correia Matos de Oliveira ◽  
Raymundo Parana
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Antiviral Treatment ◽  
Hcv Rna ◽  
Hepatocellular Injury ◽  
Autoantibody Production ◽  
Hepatitis C Treatment ◽  
Organ Specific ◽  
Treatment Naïve

Background: In the patients with hepatitis C virus (HCV) various immune mediated phenomena are described, and non organ specific autoantibodies (NOSAs) in particular are common. The aim of the present study was to investigate the NOSAs prevalence in chronic hepatitis C treatment naive patients. Patients and Methods: Sera of 76 consecutive HCV treatment naive patients were considered to be eligible for this study for evaluation of Antinuclear, antismooth muscle, antimitochondrial, antineutrophil cytoplasmatic and antiliver kidney microsomal antibodies. Criteria of eligibility were serum antiHCV antibody and HCV RNA positivity, chronic inflammation revealed by histological analysis of the liver, genotyping, treatment naive patients, and no have the diagnosis of probable or definite autoimmune hepatitis. Results: Mean chronological age for the 76 patients (44 females and 32 males) was 51.3 years (range: 20 to 67 years). Nineteen patients (25.0%) infected with HCV had detectable levels of NOSAs at before combined antiviral treatment. SMA was present in 16 (21.0%) of 76 patients, ANA in 2 patients (2.6%), and pANCA (perinuclear ANCA) in 1 patients (1.3%). No patient had specimens reactive to AMA, LMK, or cANCA (cytoplasmic ANCA). Conclusions: In this study, we show the NOSAs positivity in chronic hepatitis c treatment naive patients. Assigned to high prevalence of SMA positivity is associated with high METAVIR score, and HCV genotype 1 and 1b, may reflect a release of intracellular antigens at the time of hepatocellular injury triggering immune responses in the form of autoantibody production or a direct infection of immunocytes by the HCV. Keywords: hepatitis C, treatment naive, non organ specific antibodies, chronic liver disease

Impact of IL28B-genotype on virological response in treatment-naive Austrian patients with chronic hepatitis C

2010 ◽  
Vol 48 (05) ◽  
Author(s):  
A Staettermayer ◽  
K Rutter ◽  
S Beinhardt ◽  
TM Scherzer ◽  
K Zinober ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Virological Response ◽  
Il28b Genotype ◽  
Treatment Naïve

Real-world effectiveness of Ledipasvir/Sofosbuvir 8 weeks chronic hepatitis C treatment

2015 ◽  
Vol 53 (08) ◽  
Author(s):  
P Buggisch ◽  
J Petersen ◽  
K Wursthorn ◽  
A Gauthier ◽  
P Atanasov
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Real World ◽  
Hepatitis C Treatment
Sign in / Sign up

Export Citation Format

Share Document